Table 3.
Hazard ratios (HR) of the Cox proportional hazards model trained on the full cohort using 7 features (FSI) and 11 features (FSII) with Wald 95% confidence intervals and log-rank test p values. FIGO stage refers to the International Federation of Gynecology and Obstetrics staging system, ProMisE stands for Proactive Molecular Risk Classifier for Endometrial Cancer, MMRd – mismatch repair deficient, NSMP – no specific molecular profile, p53ab – p53 aberrant, ER – estrogen receptor status, and CD171 – L1 cell adhesion molecule (L1CAM).
| Term | HR on FSI | p value | HR on FSII | p value |
|---|---|---|---|---|
| Age | 1.04 (1.02–1.06) | 1.78E−05 | 1.04 (1.02–1.06) | 9.73E−06 |
| FIGO stage II | 1.33 (0.68–2.58) | 4.08E−01 | 1.33 (0.68–2.61) | 4.07E−01 |
| FIGO stage III | 2.73 (1.78–4.19) | 4.06E−06 | 2.2 (1.4–3.47) | 6.80E−04 |
| FIGO stage IV | 7.85 (4.35–14.16) | 7.52E−12 | 3.81 (1.9–7.63) | 1.64E−04 |
| ProMisE MMRd | 1.61 (1.05–2.47) | 3.07E−02 | 1.8 (1.17–2.77) | 7.77E−03 |
| ProMisE p53ab | 2 (1.2–3.32) | 7.57E−03 | 1.88 (1.13–3.14) | 1.51E−02 |
| Histological subgroup G3 | 2.04 (1.32–3.16) | 1.29E−03 | 1.66 (1.05–2.63) | 2.99E−02 |
| Histological subgroup Non-endometrioid | 1.35 (0.82–2.21) | 2.40E−01 | 0.95 (0.54–1.68) | 8.70E−01 |
| Deep myometrial invasion Yes | 1.25 (0.831.88) | 2.89E−01 | 1.13 (0.74–1.73) | 5.69E−01 |
| Lymphovascular invasion Yes | 1.94 (1.35–2.79) | 3.45E−04 | 2.05 (1.42–2.97) | 1.25E−04 |
| Tumor diameter > 3 cm Yes | 2.35 (1.44–3.83) | 6.49E−04 | 2.35 (1.37–3.88) | 1.39E−03 |
| Tumor diameter > 5 cm Yes | 1.29 (0.88–1.9) | 1.89E−01 | ||
| Peritoneal washing positive | 2.73 (1.68–4.43) | 4.95E−05 | ||
| ER positive | 0.7 (0.45–1.09) | 1.14E−01 | ||
| CD171 positive | 1.37 (0.97–2.17) | 1.78E−01 |